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Gait impairments in Parkinson’s disease (PD) are often present at diagnosis and respond 
selectively to treatment1. Novel interventions targeting dopa-resistant gait impairments and 
their consequences - falls risk - are urgently needed. Recent evidence suggests neuronal 
cholinergic loss from the basal forebrain (nucleus basalis of Meynert) and brainstem 
(pedunculopontine nucleus) contribute to a functional decline in gait2. A non-invasive 
technique that activates the cholinergic circuitry, which has gained recent traction in 
neurological disorders, is non-invasive vagus nerve stimulation (nVNS)3. The exact underlying 
mechanism of action of nVNS is poorly understood, but an indirect effect mediated through 
the cholinergic anti-inflammatory pathway has been postulated, through altered regulation of 
acetylcholine3. Therefore, our aim was to assess the effect of a single dose of nVNS on dopa-
resistant gait characteristics (step time variability and step length variability)4 in a pilot 
feasibility study in PD.  
Thirty participants with idiopathic PD (15 active and 15 sham) were recruited to the study. 
Participants were included if they were able to walk independently for two-minutes, had stable 
medication over the previous month and provided written consent. Those with significant 
cognitive impairment (MoCA ≤21), treated with anticholinergics and with contraindications to 
nVNS were excluded. Figure 1A displays the study design. Gait was measured within one 
hour both pre- and post- intervention during a two-minute continuous walk at a comfortable 
walking pace around a 25m circuit inclusive of a 7 x 0.6m instrumented walkway whilst ON 
dopaminergic medication. Participants in the active group received a single dose (120 
seconds) of nVNS between the pre- and post-assessments with the gammaCore® handheld 
device which was applied to the left side of the neck. For the sham group, an identical device 
delivered an electrical stimulus that did not activate the vagus nerve. Absolute and percentage 
change pre- and post-intervention were compared by treatment groups using Mann-Whitney 
tests. A significant p value was classified as ≤.05. 
Thirty-one participants were consented and 29 completed the study. There were no significant 
differences for baseline demographic (Age, gender, MDS-UPDRS part III, Hoehn and Yahr, 
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years of education and levodopa daily dose) or gait data between groups (Supplementary 
Table 1). In the active group, step time and step length variability decreased whereas an 
increase was identified in the sham group with step length variability reaching significance (-
5.6 vs. 25.4% change for active vs. control group, p=0.045) (Figure 1B).  
This exploratory study provides preliminary data suggesting dopa-resistant gait characteristics 
may improve with nVNS. The underlying mechanism of these findings may be related to 
amyloid pathology in PD, with cholinergic loss promoting amyloid-β deposition5 and amyloid-
β precipitating cholinergic neuronal loss6. However, our study is limited due to the small and 
heterogeneous cohort. Larger trials should consider using multiple treatment doses of nVNS 
and a higher intensity of stimulation as moderate stimulation has demonstrated a significant 
effect on memory consolidation in Alzheimer’s disease7. This small sham-controlled pilot study 
provides novel evidence of a potential beneficial effect of nVNS on gait in PD. Confirmation is 
required in a larger multi-dose trial.  
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